Task: Answer Verification
Input (English): Question: Is cYP2C9 Genetic Polymorphism a Potential Predictive Marker for the Efficacy of Rosuvastatin Therapy?
Answer: This study suggests that the CYP2C9 polymorphism may be involved in the lipid-lowering efficacy of rosuvastatin in patients with hyperlipidemia.
Output (English): yes